CV
ISEE

Clarus Ventures’s IVERIC bio, Inc. Common Stock ISEE Stock Holding History

Clarus Ventures’s Portfolio ISEE Stock Details ISEE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-1,554,744
Closed -$72.3M – 8
2015
Q1 		$72.3M Hold
1,554,744
– – 30.07% 1
2014
Q4 		$69.8M Hold
1,554,744
– – 19.92% 2
2014
Q3 		$60.5M Hold
1,554,744
– – 24.15% 2
2014
Q2 		$65.8M Sell
1,554,744
-1,500,000
-49% -$55M 23.36% 2
2014
Q1 		$109M Hold
3,054,744
– – 31.53% 1
2013
Q4 		$98.8M Buy
+3,054,744
New +$90.6M 27.92% 1

Other funds holding ISEE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
JCG
JHL Capital Group Chicago, Illinois $805M AUM 50.84% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SHI
SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Clarus Ventures's ISEE Position: Q2 2015 in Review

Clarus Ventures sold out of IVERIC bio, Inc. Common Stock (ISEE) in Q2 2015, closing a stake of 1,554,744 shares — an estimated $72.3M sold.

Clarus Ventures first reported a position in ISEE in Q4 2013 and held it in 6 quarters. The position peaked at $109M in Q1 2014. 139 funds tracked by Wall St. Rank hold ISEE as of Q2 2015.

  • Clarus Ventures reported no remaining IVERIC bio, Inc. Common Stock position as of Q2 2015 after selling out during the quarter.
  • Clarus Ventures sold 1,554,744 IVERIC bio, Inc. Common Stock shares in Q2 2015, an estimated $72.3M.
  • Clarus Ventures first reported a position in IVERIC bio, Inc. Common Stock in Q4 2013 and held it in 6 quarters.
  • Clarus Ventures's IVERIC bio, Inc. Common Stock position peaked at $109M in Q1 2014.
  • 139 funds tracked by Wall St. Rank held IVERIC bio, Inc. Common Stock as of Q2 2015.

Based on Clarus Ventures's 13F filing for Q2 2015, filed 30 Jul 2015.